Jiangnan Hu

This study identifies TAZ deficiency as synthetically lethal with BRAF inhibitors in anaplastic thyroid cancer, revealing a mechanism of resistance and a potential therapeutic target.

This study shows that targeting PDPK1 and BRAF V600E together is a potent therapy for anaplastic thyroid cancer, leading to tumor regression through synergistic signaling inhibition and apoptosis.

This study shows that combining BRAFV600E inhibition with ferroptosis induction synergistically kills anaplastic thyroid cancer cells by increasing iron and oxidative stress.